1,5-Anhydro-1-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-6-yl]hexitol, also known as **Taxifolin**, is a flavanonol, a type of flavonoid. It is a natural compound found in various plants, including Siberian larch (Larix sibirica), European larch (Larix decidua), and the bark of Scots pine (Pinus sylvestris).
**Here's why it's important in research:**
* **Antioxidant Properties:** Taxifolin is a potent antioxidant, scavenging free radicals and protecting cells from oxidative damage. This makes it a promising candidate for various health applications, including preventing cardiovascular disease, cancer, and neurodegenerative disorders.
* **Anti-inflammatory Effects:** Taxifolin has demonstrated anti-inflammatory activity, potentially suppressing the production of inflammatory mediators. It is being studied for its potential to treat inflammatory conditions like arthritis and inflammatory bowel disease.
* **Cardiovascular Health:** Studies suggest that Taxifolin may improve cardiovascular health by reducing blood pressure, improving blood lipid profiles, and inhibiting platelet aggregation.
* **Neuroprotective Effects:** Taxifolin shows neuroprotective effects in studies, potentially mitigating neuronal damage caused by oxidative stress and inflammation. This makes it a potential therapeutic agent for neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Cancer Prevention:** Taxifolin has shown anti-cancer effects in various studies, including inhibiting cancer cell growth and inducing apoptosis (programmed cell death). It is being investigated as a potential chemopreventive agent.
**Current Research:**
* Researchers are investigating the mechanisms by which Taxifolin exerts its beneficial effects, including its interactions with specific enzymes and signaling pathways.
* Clinical trials are ongoing to evaluate the safety and efficacy of Taxifolin in humans for various health conditions.
* Studies are exploring the potential of Taxifolin as a natural food supplement and its role in promoting overall health and well-being.
**Overall, 1,5-Anhydro-1-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-6-yl]hexitol (Taxifolin) is a promising natural compound with a broad range of biological activities. Further research is crucial to unlock its full therapeutic potential and translate its benefits into clinical applications.**
| ID Source | ID |
|---|---|
| PubMed CID | 6426860 |
| CHEMBL ID | 1302308 |
| CHEBI ID | 139455 |
| SCHEMBL ID | 14076164 |
| Synonym |
|---|
| ACON1_000742 |
| MEGXP0_000099 |
| MLS000876959 , |
| smr000440666 |
| NCGC00169402-01 |
| CHEBI:139455 |
| BRD-A41386682-001-01-4 |
| 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one |
| CHEMBL1302308 |
| HMS2270L22 |
| FT-0603655 |
| HMS3345G01 |
| SCHEMBL14076164 |
| bdbm60724 |
| 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-(3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl)chromone |
| cid_6426860 |
| 2-[3,4-bis(oxidanyl)phenyl]-6-[6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-5,7-bis(oxidanyl)chromen-4-one |
| 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one |
| ODBRNZZJSYPIDI-UHFFFAOYSA-N |
| 3',4',5,7-tetrahydroxy-6-c-glucopyranosylflavone |
| SR-01000758969-3 |
| sr-01000758969 |
| np-000286(7) |
| AKOS040740172 |
| compound np-000286 |
| Class | Description |
|---|---|
| flavonoids | Any organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them. |
| C-glycosyl compound | A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 5.5528 | 0.0032 | 45.4673 | 12,589.2998 | AID2517; AID2572 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 22.3342 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 25.1189 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 14.1254 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| endonuclease IV | Escherichia coli | Potency | 11.2202 | 0.7079 | 12.4324 | 31.6228 | AID2565 |
| WRN | Homo sapiens (human) | Potency | 31.6228 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| GLS protein | Homo sapiens (human) | Potency | 2.8184 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 1.1220 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 50.1187 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 3.9811 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 79.4328 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 11.2202 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 4.4668 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 14.1254 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| snurportin-1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 39.8107 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 11.0869 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 26.1420 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 15.8489 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 0.0015 | 51.7393 | 15,848.9004 | AID2572 |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 0.0141 | 8.6024 | 39.8107 | AID2572 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 35.4813 | 0.0757 | 8.4742 | 29.0628 | AID602233 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | IC50 (µMol) | 0.8719 | 0.0795 | 3.5203 | 9.9390 | AID1053171; AID1053172 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 (µMol) | 0.8719 | 0.0795 | 3.5203 | 9.9390 | AID1053171; AID1053172 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 42.9400 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
| Vif | Human immunodeficiency virus 1 | IC50 (µMol) | 12.6600 | 0.2700 | 34.0015 | 100.0000 | AID1117319 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 12.6600 | 0.2700 | 26.3638 | 100.0000 | AID1117319 |
| large T antigen | Betapolyomavirus macacae | IC50 (µMol) | 5.2300 | 0.1600 | 24.9724 | 100.0000 | AID1903 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Glutamate receptor 1 | Rattus norvegicus (Norway rat) |
| plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||